Pfizer is facing significant revenue and earnings declines, primarily due to patent expirations of leading drugs. See why I still rate PFE stock a strong buy.

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer: Performance Is Improving, But Secular Issues Persist (Rating Upgrade) Aug. 23, 2024 4:29 AM ET Pfizer Inc. (PFE) Stock , PFE:CA Stock PFE , PFE:CA 17 Comments 3 Likes KM Capital ...

While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today. And you ...

Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company ...

Pfizer (NYSE: PFE) is scheduled to report its Q1 2024 results on Wednesday, May 1. We expect the company to post revenue of $13.8 billion and earnings of $0.50 on a per share and adjusted basis.

Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

Firstly, let us look at Pfizer’s stock performance in recent years. PFE stock has faced a decline of 15% from levels of $35 in early January 2021 to around $30 now, vs. an increase of about 45% ...

Pfizer ( (PFE)) has been popular among investors this week. Here is a recap of the key news on this stock. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment ...

Pfizer is now more focused on innovative drugs and vaccines, analyst says Last Updated: Feb. 4, 2025 at 12:58 p.m. ET First Published: Feb. 4, 2025 at 7:09 a.m. ET Share ...